Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andevil and Focus V with Chemotherapy in Advanced ESCC
NCT05013697Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of catequentinib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
catequentinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05013697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013697.